BCL2 mutation	Follicular Lymphoma	BCL2 mutation	Follicular Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials nivolumab + ibrutinib Sensitive : C3	nivolumab + ibrutinib Sensitive: C3 – Early Trials nivolumab + ibrutinib Sensitive : C3
BCL2 mutation	Diffuse Large B Cell Lymphoma	BCL2 mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
BCL2 mutation	Acute Myelogenous Leukemia	BCL2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
BCL2 mutation	Multiple Myeloma	BCL2 mutation	Multiple Myeloma	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
BCL2 mutation	Chronic Lymphocytic Leukemia	BCL2 mutation	Chronic Lymphocytic Leukemia	NX-2127 Sensitive: C3 – Early Trials NX-2127 Sensitive : C3	NX-2127 Sensitive: C3 – Early Trials NX-2127 Sensitive : C3
BCL2 mutation	Chronic Lymphocytic Leukemia	BCL2 mutation	Chronic Lymphocytic Leukemia	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D

BCL2 mutation

Associations